KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $30.7 million.

  • Esperion Therapeutics' Current Deferred Revenue rose 103.47% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 103.47%. This contributed to the annual value of $8.5 million for FY2024, which is 66.47% down from last year.
  • Per Esperion Therapeutics' latest filing, its Current Deferred Revenue stood at $30.7 million for Q3 2025, which was up 37.49% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Current Deferred Revenue ranged from a high of $30.7 million in Q3 2025 and a low of $2.5 million during Q1 2021.
  • Over the past 3 years, Esperion Therapeutics' median Current Deferred Revenue value was $19.7 million (recorded in 2023), while the average stood at $18.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 624.32% in 2023, then tumbled by 84.52% in 2025.
  • Esperion Therapeutics' Current Deferred Revenue (Quarterly) stood at $5.7 million in 2021, then tumbled by 38.29% to $3.5 million in 2022, then spiked by 624.32% to $25.4 million in 2023, then plummeted by 66.47% to $8.5 million in 2024, then surged by 103.47% to $30.7 million in 2025.
  • Its Current Deferred Revenue was $30.7 million in Q3 2025, compared to $22.3 million in Q2 2025 and $4.5 million in Q1 2025.